ESR1 and cancer: About 70% of newly diagnosed invasive BCs express estrogen receptor alpha (ERα), a ligand-inducible transcription factor, and the presence of this receptor identifies tumors likely to respond to endocrine therapies, based on the use of antiestrogens (AEs) or aromatase inhibitors to block its activity in cancer cells.